Teva Pharmaceutical Industries has agreed to make an initial investment of US$7.5 M in Cocrystal Discovery (CDI), a developer of small molecule antiviral drugs, in order to gain the right to license exclusive development and commercialisation rights to drugs targeting hepatitis C virus (HCV) polymerase. Teva also has the option to invest further in CDI upon completion of the initial development plan for this programme and in order to advance the development of two additional antiviral or antibacterial drugs. If it chooses to make all of these investments, Teva will own 23% of the company.